361: Serum Levels of Angiogenin and Vascular Endothelial Growth Factor (VEGF) Predict Metastatic Disease in Renal Cell Cancer Patients

2005 ◽  
Vol 173 (4S) ◽  
pp. 99-99 ◽  
Author(s):  
Marcus Horstmann ◽  
Axel S. Merseburger ◽  
Markus A. Kuczyk ◽  
Arnulf Stenzl ◽  
Karl-Horst Bichler ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Renal Cell Cancer ◽  
Metastatic Disease ◽  
Renal Cell ◽  
Cell Cancer ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Vascular Endothelial Growth Factor (VEGF) Serum Levels during Cancer Immunotherapy with IL-2: Preliminary Considerations

1998 ◽  
Vol 13 (2) ◽  
pp. 98-101 ◽  
Author(s):  
P. Lissoni ◽  
L. Fumagalli ◽  
L. Giani ◽  
F. Rovelli ◽  
G Confalonieri ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Immunotherapy ◽  
Cancer Patients ◽  
Cell Cancer ◽  
Free Fraction ◽  
Serum Levels ◽  
Angiogenic Factor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Neoangiogenesis has been proven to play a fundamental role in promoting cancer spread, and vascular endothelial growth factor (VEGF) is known to represent one of the most important angiogenic factors. The present study was planned to investigate changes in VEGF secretion in cancer patients undergoing immunotherapy with IL-2, with the aim of establishing whether VEGF variations play a role in mediating the IL-2-induced control of neoplastic diseases. The study involved 14 metastatic renal cell cancer patients treated with IL-2 immunotherapy (6 million IU/day subcutaneously for 6 days/week for 4 weeks). The clinical response consisted of partial response (PR) in 3, stable disease (SD) in 6 and progressive disease (PD) in the remaining 5 patients. VEGF serum levels were measured by an enzyme immunoassay designed to determine both bound and unbound VEGF. No significant changes in VEGF mean levels occurred during IL-2 therapy. Moreover, neither in patients with PR or SD nor in those with PD did the mean serum levels of VEGF change significantly in response to IL-2. This preliminary study seems to exclude that changes in the angiogenic factor VEGF may play a role in mediating the therapeutic efficacy of IL-2 cancer immunotherapy. However, since the method of measurement used in our study was designed to detect the total amount of VEGF, it cannot be excluded that changes in the free fraction of the molecule may occur during IL-2 cancer immunotherapy.

Novelties of treatment in advanced renal-cell cancer

2011 ◽  
Vol 152 (17) ◽  
pp. 655-662 ◽  
Author(s):  
Anikó Maráz
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Tyrosine Kinase ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Current Evidence ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Advanced Renal Cell Cancer

Therapeutic options in advanced renal-cell cancer have expanded through better understanding of molecular patho­logy and development of novel targeted therapeutics. Vascular endothelial growth factor, the key ligand of angioge­nesis, has a major role in the progression of vascularized kidney tumors and this is the target molecule of modern medications. The three types of the mechanism of action of current therapies are: monoclonal antibodies blocking directly vascular endothelial growth factor ligand (bevacizumab), tyrosine-kinase inhibitors blocking vascular endothelial growth factor receptors (sorafenib, sunitinib, pazopanib) and inhibitors of the intracellular mTOR-kinase (temsirolimus, everolimus). Based on randomized studies, sunitinib, pazopanib or interferon-α-bevacizumab combination should be the first-line therapy in patients with good/moderate prognosis, while temsirolimus is recommended in those with poor prognosis. Following an ineffective cytokine therapy sorafenib or pazopanib are the se­cond-line treatment. In case of tyrosine-kinase inhibitor inefficacy, current evidence favors everolimus. Patient outcome can further be improved by the involvement of more modern and effective target products. Orv. Hetil., 2011, 152, 655–662.

The expression of RUNX3 gene in renal cell cancer and its clinical relevance with serum vascular endothelial growth factor

2017 ◽  
Vol 2 (2) ◽  
pp. 73
Author(s):  
Kalpesh Mahesh Parmar ◽  
Mamta Singla ◽  
Arup Kumar Mandal ◽  
Shalmoli Bhattacharya ◽  
Sharwan Kumar Singh
Keyword(s):  
Gene Expression ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Renal Cancer ◽  
Tumor Tissue ◽  
Cell Cancer ◽  
Vascular Endothelial ◽  
Runx3 Gene ◽  
Endothelial Growth Factor

<p>Background: Latest advances indicate that RUNX3 is a candidate tumor suppressor in several types of human cancers, including renal cell cancer.<br />However, its definitive role is not yet established. Vascular endothelial growth factor (VEGF) has been widely studied as a surrogate marker of<br />angiogenic activity and prognostic marker in renal cancer for monitoring treatment response and detection of early relapse. The aim of the study was<br />to examine the clinical significance of RUNX3 expression and serum VEFG in series of renal cancer patients using quantitative real-time polymerase<br />chain reaction and standard enzyme-linked immunosorbent assay kit and find its correlation with renal cancer stage, grade, and histopathology.<br />Materials and Methods: We reviewed our prospectively collected renal cancer database of 47 patients. All patients were evaluated preoperatively<br />and staged and underwent partial or radical nephrectomy as per the feasibility criteria. RUNX 3 expression in tumor tissue and adjoining parenchyma<br />was sampled in all patients, and serum levels of VEGF were measured in pre-and post-operative period on day 7 and day 30 after surgery. 10<br />age- and sex-matched healthy volunteers served as control group. Results: We observed that RUNX3 gene expression was significantly lower in<br />tumor tissue than in normal renal parenchyma of a renal cancer patient. The serum VEGF levels were significantly increased in patients with renal<br />cell carcinoma (RCC) compared to normal healthy volunteers and showed decreasing trend after the surgery. Loss of RUNX3 gene expression<br />and higher VEGF levels strongly correlated with high-grade tumors; however, it was not related to tumor size and histopathology. There was no<br />correlation of RUNX 3 with VEGF levels in RCC patients. Conclusion: The results of this study showed that renal cancer patients had increased<br />VEGF levels which were effectively alleviated by curative resection. Lower expression of RUNX3 in renal cancer suggests its tumor suppressive<br />role and new insights into targeted therapies linking RUNX3 gene may have some diagnostic and therapeutic implications in RCC patients. We did<br />not find any correlation between RUNX3 gene and serum VEGF.</p>

Vascular Endothelial Growth Factor (VEGF) Serum Levels Are Associated With Survival in Early Stages of Lung Cancer Patients

2010 ◽  
Vol 28 (4) ◽  
pp. 393-398 ◽  
Author(s):  
Enrique Carrillo-de Santa Pau ◽  
Fernando Carrillo Arias ◽  
Enrique Caso Pelaez ◽  
Ignacio Muguruza Trueba ◽  
Ignacio Sánchez Hernández ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Lung Cancer Patients ◽  
Early Stages ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document